Leukocyte count and the risk of adverse outcomes in patients with HFpEF.

ABSTRACT:

Background

Inflammation is a key feature of heart failure including HFpEF. The leukocyte count is a marker of inflammation that is widely used in clinical practice. However, there is little available evidence for the relationship between leukocyte count and the outcomes of HFpEF.

Methods

We analyzed data from the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist) trial. The primary outcome was all-cause mortality, the secondary outcome was composite cardiovascular events and hospitalization for heart failure. Multivariable Cox proportional hazard models were used to compare the risk profiles of patients with leukocyte quartiles, subgroup study divided by sex was also analyzed.

Results

The present study included 2898 patients

SUBMITTER: Zhu Z 

PROVIDER: S-EPMC8261982 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature